Alicia Lenzen

  • 52 Citations
20152018
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Training Experience

2015Internship, Advocate Christ Medical Center/Advocate Children's Hospital
2015Residency, Advocate Children's Hospital, Oak Lawn
2018Fellowship, Northwestern University, McGaw Medical Center (Lurie Children's Hospital)
2019Fellowship, Northwestern University, McGaw Medical Center (Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

Education/Academic qualification

MD, Brown University

… → 2011

Fingerprint Dive into the research topics where Alicia Lenzen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Glioblastoma Medicine & Life Sciences
Indoleamine-Pyrrole 2,3,-Dioxygenase Medicine & Life Sciences
Vaccines Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Kynurenine Medicine & Life Sciences
Thrombasthenia Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Central Nervous System Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2015 2018

  • 52 Citations
  • 5 Article
  • 2 Review article
  • 1 Editorial

Clinical Trials 101 in Pediatric Oncology Patients

Lenzen, A. & Smiley, N. P., Jun 1 2018, In : Clinical Pediatric Emergency Medicine. 19, 2, p. 131-134 4 p.

Research output: Contribution to journalArticle

Clinical Trials
Pediatrics
Hospital Emergency Service
Therapeutics
Neoplasms
24 Citations (Scopus)

IDO1 in cancer: a Gemini of immune checkpoints

Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M. & Wainwright, D. A., May 1 2018, In : Cellular and Molecular Immunology. 15, 5, p. 447-457 11 p.

Research output: Contribution to journalReview article

Indoleamine-Pyrrole 2,3,-Dioxygenase
Neoplasms
Tryptophan
Kynurenine
Essential Amino Acids
18 Citations (Scopus)

IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma

Ladomersky, E., Zhai, L., Lenzen, A., Lauing, K. L., Qian, J., Scholtens, D. M., Gritsina, G., Sun, X., Liu, Y., Yu, F., Gong, W., Liu, Y., Jiang, B., Tang, T., Patel, R., Platanias, L. C., James, C. D., Stupp, R., Lukas, R. V., Binder, D. C. & 1 others, Wainwright, D. A., Jun 1 2018, In : Clinical Cancer Research. 24, 11, p. 2559-2573 15 p.

Research output: Contribution to journalArticle

Glioblastoma
Radiation
Survival
T-Lymphocytes
Therapeutics

Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma

Binder, D. C., Ladomersky, E., Lenzen, A., Zhai, L., Lauing, K. L., Otto-Meyer, S. D., Lukas, R. V. & Wainwright, D. A., Apr 1 2018, In : Translational Cancer Research. 7, p. S510-S513

Research output: Contribution to journalEditorial

Glioblastoma
Therapeutics
epidermal growth factor receptor VIII
rindopepimut

Pediatric Central Nervous System Tumor Diagnosis, Complications, and Emergencies

Lenzen, A., Garcia-Sosa, R., Habiby, R. L., DiPatri, A. J. & Pillay Smiley, N., Jun 1 2018, In : Clinical Pediatric Emergency Medicine. 19, 2, p. 153-161 9 p.

Research output: Contribution to journalArticle

Central Nervous System Neoplasms
Emergencies
Pediatrics
Neurogenic Diabetes Insipidus
Neoplasms